Sun BioPharma Progresses in Its Pursuit of Therapeutics for Pancreatic Cancer (GlobeNewswire)

UF startup Sun BioPharma, Inc., a biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic diseases, reported additional progress in the Phase 1 Study of the Company’s candidate SBP101 for pancreatic cancer.  The Study’s Data Safety Monitoring Board (DSMB) has completed its independent safety review of the data from the dosing of the second cohort of patients.  As a result of this review, the Company has implemented progression to the third patient cohort in the dose escalation phase of the study.

ViewRay (VRAY) Approved to Market MRIdian System in Japan (StreetInsider)

UF startup ViewRay, Inc. announced that the company received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the MRIdian System. MRIdian is the world’s first and only clinical MRI-guided radiation therapy system. Japan is the world’s third largest market for radiation oncology, and this approval represents a significant step in ViewRay’s geographic expansion. ViewRay is represented in Japan by ITOCHU Corporation, one of the three largest general trading companies in Japan. ITOCHU has been focusing on the healthcare business to promote important medical innovations in Japan for approximately 40 years.

Former Gates Foundation and Baxter Executive Peter H. Khoury, Ph.D. Joins Nanotherapeutics as Chief Commercial Officer (BusinessWire Company Press Release)

Nanotherapeutics, Inc., a contract development and manufacturing organization (CDMO) based on University of Florida research, announced that Peter Khoury, Ph.D. has joined the company as Senior Vice President and Chief Commercial Officer. Dr. Khoury was with the Bill & Melinda Gates Foundation, serving as Senior Program Officer, Life Science Partnerships, Office of the President for Global Health. Prior to his tenure with the Gates Foundation, from 2002 to 2012, Dr. Khoury was Vice President, Global Marketing at Baxter International, where he led the development and implementation of the company’s vaccines business strategies, product management, business plans, and ex-European vaccine sales.

ViewRay is “Best-Performing Company” in Ohio on Forbes List (Dayton Business Journal)

A Cleveland company based on UF research was listed as the best performer in Ohio on Forbes magazine’s list, “Best Performing Company in Each State”. ViewRay also posted the best rate of return of any company on the list: 3,700 percent between June 8, 2015, and June 8, 2016. ViewRay designs, manufactures and markets the MRIdian radiation therapy system.

Inventor Says Fame Is Fine, But Best Reward is Helping Others (Gainesville Sun)

As a microbiology professor at the University of Florida, Nicholas Muzyczka figured out a way to engineer a virus to deliver genetic material that would continue to replicate in the body. He later co-founded UF startup AGTC. The discovery in the 1980s would form the basis for most of the work developing treatments for genetic diseases, including potential treatments for eye, neurodegenerative, pulmonary and cardiovascular diseases, according to the University of Florida. For his work, Muzyczka, 65, will be inducted into the Florida Inventors Hall of Fame Sept. 16 in Tampa.

Molekule Air Filter Is Obsessed With Destroying Pollutants (The Verge)

A lot of people who suffer from allergies hide inside their houses — especially in the spring. But your indoor air could be up to five times more polluted, according to the Environmental Protection Agency. To solve that problem, a company called Molekule is launching the first molecular air purifier — a two-foot-tall cylinder that sucks in and destroys the stuff that pollutes your air — based on UF research.

Florida Biotech AGTC Plans Growth of Cambridge Offices This Year (Boston Business Journal)

Sue Washer has a list of reasons she likes the Gainesville, Florida area for her gene therapy startup, Applied Genetic Technologies Corp. Among them are low corporate costs compared to other biotech hubs, proximity to University of Florida — “one of the best-known gene therapy colleges in the country” — and less competition for new hires.

The company recently expanded to Cambridge, Mass.

AxoGen First Quarter Revenue Increases 64% Over Prior Year to $8.1M (Globe NewsWire)

AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries based on UF technology, recently reported financial results for the first quarter ended March 31, 2016 and recent corporate developments. Among these results, fiirst quarter revenue of $8.1 million increased approximately 64% over the prior year.